Kiadis Pharma N.V. Appoints Karl Hård as Head of Investor Relations and Communications
September 05, 2017 at 01:00 am EDT
Kiadis Pharma N.V. announced the appointment of Dr. Karl Hård as Head of Investor Relations and Communications. Karl has spent almost 20 years at AstraZeneca PLC based in Sweden and the UK. Over a period of 10 years, he held senior roles within Investor Relations, latterly as head of IR. Prior to that, he worked as Global Program Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. Karl’s scientific experience covers numerous fields, including oncology and immunology, as evidenced by over 40 published scientific articles in peer-reviewed international journals.